A C. diff (Clostridioides difficile ... co-administered a probiotic supplement showed a lower risk of Clostridium difficile infections. The study authors concluded moderate-quality evidence ...

This indicator covers the incidence of healthcare associated infections from Clostridium difficile (C. diff). It measures outcomes that reflect the quality of care or processes linked by evidence to ...

Q. My son picked up an infection in the hospital recently. It sounded like the doctors were calling it “see-dift.” It gave him terrible diarrhea. Do you know what this is? A. The doctors were ...

Pfizer's vaccine for Clostridium difficile (C. diff ... of PF-06425090 was undermined by a lower-than expected rate of C. diff infection (CDI) as a result of social isolation caused by the ...

35–49 years old 0.98 (0.74, 1.31) 0.84 (0.61, 1.14) 0.82 (0.49, 1.38) 1.49 (0.96, 2.33) 50–64 years old 1.27 (0.97, 1.65) 1.34 (1.00, 1.78) 0.84 (0.53, 1.33) 1.92 (1.19, 3.11) 65 years old or ...

EP: 12.Common Comorbidities Associated With Recurrent C Difficile Infections ...

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed.

Video content above is prompted by the following: What are the main unmet needs for recurrent C difficile infections and how do you see the field evolving in the future?

Recurrent Clostridium difficile (C diff) infection is a hard-to-treat gastrointestinal (GI) infection that causes 29,000 deaths every year in the US alone. Studies have shown that most cases of C ...

Clostridium perfringens is a significant ... This overview highlights the latest findings in the field of C. perfringens infections and toxinology. Recent studies have shed light on the prevalence ...